2021抗癌新药出炉！十大癌症，上百种新药免花费的机会来了
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2020年即将步入尾声，<span style="color: black;">针对</span>肿瘤<span style="color: black;">病人</span><span style="color: black;">来讲</span>，今年靶向疗法，免疫疗法上市的好<span style="color: black;">信息</span><span style="color: black;">持续</span>，FDA共<span style="color: black;">准许</span>了近50种新疗法，覆盖了十大实体肿瘤，又有<span style="color: black;">非常多</span>幸运的病友们等来了新的<span style="color: black;">期盼</span>和治疗<span style="color: black;">选取</span>！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">除此之外，国内以及国际上还有众多在研的新药取得了重大突破，<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部为<span style="color: black;">大众</span>整理了2020-2021年度最新的十大肿瘤抗癌新药。即日起，病友们可<span style="color: black;">经过</span><span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部申请这些抗癌新药，有机会入组拉罗替尼，恩曲替尼，安罗替尼，PD-1，癌症疫苗等抗癌<span style="color: black;">药品</span>的<span style="color: black;">关联</span>临床<span style="color: black;">实验</span>，免费接受这些“天价”最新抗癌<span style="color: black;">药品</span>的治疗。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">不限癌种（适合所有实体肿瘤）</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1拉罗替尼</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NTRK</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">最终</span>来了！堪<span style="color: black;">叫作</span>天价的“治愈系”抗癌药拉罗替尼正式在国内开展临床<span style="color: black;">实验</span>！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">拉罗替尼是<span style="color: black;">全世界</span>首款<span style="color: black;">获准</span>的NTRK<span style="color: black;">控制</span>剂，在TRK融合癌<span style="color: black;">病人</span>的三项大型临床<span style="color: black;">实验</span>汇总数据<span style="color: black;">表示</span>，拉罗替尼的总缓解率高达ORR为75％，其中22％的<span style="color: black;">病人</span>完全缓解。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2恩曲替尼</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NTRK/ALK/ROS1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">中国NTRK基因融合临床招募近况<span style="color: black;">颁布</span>！100+<span style="color: black;">病人</span>有望入组“治愈系”抗癌药恩曲替尼治疗</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">恩曲替尼是<span style="color: black;">全世界</span><span style="color: black;">获准</span>的第二款NTRK<span style="color: black;">控制</span>剂，在TRK融合癌<span style="color: black;">病人</span>的临床<span style="color: black;">实验</span>汇总数据<span style="color: black;">表示</span>，客观缓解率ORR（肿瘤缩小）为57.4%，并且在横跨10种不同类型肿瘤中均观察到了客观缓解（肿瘤缩小）。存在脑转移的<span style="color: black;">病人</span>中，entrectinib的颅内客观缓解率ORR为54.5%，其中超过25%实现完全缓解（病灶<span style="color: black;">所有</span>消失）。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3ICP723</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NTRK</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">一项<span style="color: black;">评估</span> ICP-723 在实体瘤<span style="color: black;">病人</span>中的安全性、耐受性、药代动力学的多中心、非随机、开放性Ⅰ/Ⅱ期临床<span style="color: black;">实验</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">ICP-723是一种国内<span style="color: black;">开发</span>的第二代泛酪氨酸受体激酶（泛TRK）小分子抑制剂，用于治疗不同肿瘤类型的神经营养性酪氨酸激酶（NTRK）阳性的肿瘤<span style="color: black;">病人</span>以及<span style="color: black;">因为</span>抗性TRK基因突变而对<span style="color: black;">第1</span>代酪氨酸激酶（TRK）<span style="color: black;">控制</span>剂产生耐药性的<span style="color: black;">病人</span>。2019年3月17日，ICP-723片申报临床<span style="color: black;">实验</span>申请，即将<span style="color: black;">起始</span>临床<span style="color: black;">实验</span>并招募<span style="color: black;">病人</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">4TL118</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NTRK</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">TL118胶囊在NTRK基因融合的晚期恶性实体瘤<span style="color: black;">病人</span>中的安全性、耐受性、药代动力学特征的剂量递增、开放的I期临床<span style="color: black;">实验</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">TL118胶囊是一款国产“不限癌种”NTRK融合基因突变靶向药，<span style="color: black;">全世界</span>上市的<span style="color: black;">一样</span>用于治疗NTRK融合基因实体瘤的<span style="color: black;">药品</span>有两个，分别是拜耳/LOXO的拉罗替尼（2018年11月被FDA<span style="color: black;">准许</span>上市）以及罗氏的恩曲替尼（2019年8月被FDA<span style="color: black;">准许</span>上市）。<span style="color: black;">日前</span>国内已开展TL118治疗晚期NTRK融合实体肿瘤的临床<span style="color: black;">实验</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">5AB-106</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NTRK/ROS1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">燃！第二代ROS1/NTRK双靶点抗癌药Taletrectinib最新晚期实体瘤数据<span style="color: black;">颁布</span>！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Talectrectinib代号为DS-6051b/AB-106，是一款新型、有效、<span style="color: black;">选取</span>性高的下一代ROS1和NTRK双靶点小分子<span style="color: black;">控制</span>剂，可穿越血脑屏障。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">6SIM-201</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">NTRK/ROS1/ALK</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">接棒“治愈系神药”！多款二代NTRK<span style="color: black;">控制</span>剂震撼亮相，力克耐药突变！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">SIM-201是自主<span style="color: black;">开发</span>的二代抗肿瘤NTRK多激酶小分子<span style="color: black;">控制</span>剂，能够潜在靶向NTRK、ROS1和ALK原发性突变和NTRK、ROS1继发性耐药突变，已<span style="color: black;">得到</span>新药临床批文，并计划于2020年底之前在中国<span style="color: black;">起步</span>I期临床<span style="color: black;">实验</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">7HWH-340</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">BRCA1/2等</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">即将<span style="color: black;">颁布</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">导致</span>同源重组修复缺陷（HRD）的<span style="color: black;">原由</span><span style="color: black;">非常多</span>，包括胚系BRCA1/2突变、体系BRCA1/2突变、HRR突变等等，在癌症基因检测中经常检测的BRCA突变，只是同源重组修复缺陷的其中一个<span style="color: black;">原由</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">HWH340是一款PARP<span style="color: black;">控制</span>剂，但与绝大<span style="color: black;">都数</span>PARP<span style="color: black;">控制</span>剂不同，这款<span style="color: black;">药品</span>，<span style="color: black;">能够</span>用于治疗因<span style="color: black;">各样</span><span style="color: black;">原由</span>而<span style="color: black;">引起</span>的、存在同源重组修复缺陷的癌症<span style="color: black;">病人</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">8HTMC0435</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">BRCA1/2等</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">评估</span>HTMC0435片单次和多次给药在晚期恶性实体瘤<span style="color: black;">病人</span>中的安全性和耐受性，探索最大耐受剂量(MTD)和剂量限制性毒性(DLT)，<span style="color: black;">知道</span>II期临床<span style="color: black;">举荐</span>给药剂量（RP2D）</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">非临床<span style="color: black;">科研</span>结果<span style="color: black;">显示</span>，HTMC0435是一种针对PARP1及PARP2的<span style="color: black;">有效</span><span style="color: black;">选取</span>性抑制剂，对体外PAPR酶<span style="color: black;">控制</span>活性以及对多种体外肿瘤细胞增殖<span style="color: black;">控制</span>活性均强于Olaparib，对多种<span style="color: black;">身体</span>移植瘤模型（尤其是BRCA1/2突变的肿瘤模型）的抑瘤效果<span style="color: black;">亦</span><span style="color: black;">明显</span>优于Olaparib，最大可致肿瘤完全消退。<span style="color: black;">同期</span>，HTMC0435<span style="color: black;">亦</span><span style="color: black;">拥有</span>良好的药代动力学特征，安全性<span style="color: black;">危害</span><span style="color: black;">亦</span>在可接受范围。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">9RX-108</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PI3K突变的实体瘤、STK11</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">全新的抗癌靶标！关闭增殖、<span style="color: black;">起步</span>凋亡与自噬，让癌细胞“自取灭亡”！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">RX108是润新生物自主<span style="color: black;">开发</span>的全新小分子Na+/K+-ATP酶<span style="color: black;">控制</span>剂。Na+/K+-ATP酶是强心苷类<span style="color: black;">药品</span>的<span style="color: black;">重点</span><span style="color: black;">功效</span>靶点，新的<span style="color: black;">科研</span><span style="color: black;">显示</span>它与肿瘤细胞的<span style="color: black;">出现</span>、发展、迁移及分化<span style="color: black;">关联</span>，<span style="color: black;">控制</span>Na+/K+-ATP酶可<span style="color: black;">经过</span>多种途径发挥抗肿瘤<span style="color: black;">功效</span>，为研制新型抗肿瘤<span style="color: black;">药品</span>开辟了一个新的途径。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">10RX-208</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">BRAF V600E</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">初步<span style="color: black;">评估</span>RX208在BRAF V600E突变阳性的晚期恶性实体肿瘤<span style="color: black;">病人</span>中的抗肿瘤疗效</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">RX208由润新生物自主<span style="color: black;">开发</span>，是一款针对BRAF V600E突变的<span style="color: black;">选取</span>性小分子<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>。RX208是继RX108（全新小分子Na+/K+-ATP酶<span style="color: black;">控制</span>剂）和RX518（第三代全新小分子表皮生长因子受体酪氨酸激酶<span style="color: black;">控制</span>剂）后，润新生物自主<span style="color: black;">开发</span>的第三个进入临床<span style="color: black;">实验</span>的1类新药。RX208<span style="color: black;">拥有</span><span style="color: black;">药品</span>活性强、<span style="color: black;">选取</span>性高的优点，<span style="color: black;">将来</span>有望<span style="color: black;">研发</span>成为更加安全、有效的BRAF V600E突变小分子<span style="color: black;">控制</span>剂，造福<span style="color: black;">更加多</span><span style="color: black;">病人</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">11WX390</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PI3K/mTOR</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">评估</span>WX390治疗晚期恶性实体瘤或淋巴瘤<span style="color: black;">病人</span>的安全性和耐受性，并探索最大耐受剂量，确定Ⅱ期临床<span style="color: black;">实验</span><span style="color: black;">举荐</span>剂量。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">WXFL10030390（WX390）是一款针对PI3K/mTOR靶点的小分子<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>，由嘉坦医药<span style="color: black;">开发</span>。PI3K-Akt-mTOR通路在细胞的生长、分化、凋亡等各个生理过程中都发挥着至关<span style="color: black;">要紧</span>的<span style="color: black;">功效</span>，其信号通路<span style="color: black;">反常</span>可能<span style="color: black;">出现</span>于各类癌种中。PI3K为通路上游，mTOR为通路下游，均有<span style="color: black;">药品</span><span style="color: black;">开发</span>。三阴性乳腺癌、胃癌、小细胞肺癌等<span style="color: black;">日前</span>靶向治疗效果欠佳的癌种均可能存在<span style="color: black;">必定</span>比例的PI3K-Akt-mTOR通路<span style="color: black;">反常</span>，<span style="color: black;">因此呢</span>针对这一通路的靶向<span style="color: black;">药品</span><span style="color: black;">拥有</span>多癌种或泛癌种的治疗<span style="color: black;">潜能</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">12普维替尼</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">HER2</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">普维替尼在HER2表达阳性晚期实体瘤<span style="color: black;">病人</span>中的耐受性及药代动力学<span style="color: black;">科研</span>：一项单臂、开放、剂量爬坡设计的单次和多次给药的Ⅰa期临床<span style="color: black;">科研</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">普维替尼是一款由我国自主<span style="color: black;">开发</span>的1.1类新药，属于一种小分子<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>，<span style="color: black;">针对</span>HER2靶点有较好的<span style="color: black;">控制</span>力，其治疗效果与曲妥珠单抗<span style="color: black;">类似</span>，<span style="color: black;">同期</span><span style="color: black;">拥有</span>治疗多种实体瘤的<span style="color: black;">潜能</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">13T601</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">/（溶瘤病毒）</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">用病毒“杀瘤”的颠覆性创新科技！激发<span style="color: black;">病人</span>全身免疫功能、向癌症宣战！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">溶瘤病毒是一种经过基因人工修饰或自然<span style="color: black;">选取</span>之后的特殊病毒，它们能够对癌细胞<span style="color: black;">导致</span>杀伤，但不会<span style="color: black;">损伤</span>正常的人体细胞。究其<span style="color: black;">原由</span>，经过基因修饰之后的溶瘤病毒<span style="color: black;">没</span>法阻止细胞“<span style="color: black;">自s</span>”，<span style="color: black;">因此呢</span>在它感染健康细胞后，健康细胞<span style="color: black;">能够</span><span style="color: black;">经过</span>“<span style="color: black;">自s</span>”来阻止病毒的复制及在<span style="color: black;">周边</span>传播；而癌细胞<span style="color: black;">已然</span>放弃了“<span style="color: black;">自s</span>”的能力，<span style="color: black;">因此呢</span>溶瘤病毒<span style="color: black;">能够</span>安心地在这个不会死亡的细胞中复制，并将它“撑爆”，释放<span style="color: black;">更加多</span>溶瘤病毒进入肿瘤病灶之中。由我国自主<span style="color: black;">开发</span>的溶瘤病毒制剂T601是重组溶瘤痘苗病毒注射液，具备靶向溶瘤和靶向化疗的双重<span style="color: black;">功效</span>：<span style="color: black;">经过</span>对野生型痘苗病毒进行基因改造(敲除胸苷激酶TK和核酸还原酶RR基因)，实现靶向溶瘤的<span style="color: black;">功效</span>；<span style="color: black;">插进</span><span style="color: black;">自s</span>基因Fcu1，<span style="color: black;">能够</span>将5-氟胞嘧(一种<span style="color: black;">没</span>毒的口服前药)转化为5-氟尿嘧啶，实现靶向化疗的效果。<span style="color: black;">日前</span>治疗晚期恶性实体肿瘤<span style="color: black;">病人</span>的临床<span style="color: black;">实验</span>正在招募<span style="color: black;">病人</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">14莱古比星</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">/（化疗药）</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">7倍完全缓解率！泛癌种化疗新药莱古比星横空出世，临床<span style="color: black;">实验</span>招募中</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">莱古比星是一类我国自主<span style="color: black;">开发</span>的新型蒽环类化疗<span style="color: black;">药品</span>，基于多柔比星偶联而成，<span style="color: black;">能够</span>降低<span style="color: black;">药品</span>的心脏毒性及其对免疫系统<span style="color: black;">导致</span>的<span style="color: black;">损害</span>，<span style="color: black;">同期</span>延长<span style="color: black;">药品</span>在<span style="color: black;">病人</span><span style="color: black;">身体</span>的半衰期，<span style="color: black;">同期</span>能够达到在<span style="color: black;">控制</span>肿瘤生长的<span style="color: black;">同期</span>促进抗肿瘤免疫反应的双重效果。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">因为</span><span style="color: black;">这般</span>的特点，与多柔比星相比，莱古比星<span style="color: black;">针对</span>正常细胞的<span style="color: black;">损伤</span>更小，<span style="color: black;">导致</span>的心脏毒性、过敏性、溶血性及血管与肌肉刺激性更小，安全性更高。临床前<span style="color: black;">实验</span>证实，莱古比星联合PD-1<span style="color: black;">控制</span>剂治疗，完全缓解率<span style="color: black;">达到</span>到多柔比星联合PD-1<span style="color: black;">控制</span>剂的7倍！<span style="color: black;">同期</span>，莱古比星<span style="color: black;">针对</span>肝内病灶及骨转移有良好的治疗效果。<span style="color: black;">日前</span>，莱古比星的Ⅰ期临床<span style="color: black;">实验</span>正在招募<span style="color: black;">病人</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">15C019199片</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">/</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">免疫细胞被癌细胞“策反”了怎么办？用CSF1R<span style="color: black;">控制</span>剂让它“清醒”一下！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">C019199片是一款由我国药企福建海西新药创制自主<span style="color: black;">开发</span>的创新<span style="color: black;">药品</span>，<span style="color: black;">已然</span>于近期<span style="color: black;">得到</span>国家<span style="color: black;">药物</span>监督管理局<span style="color: black;">准许</span>，正在进行Ⅰ期临床<span style="color: black;">实验</span>（CTR20202045），用于治疗结直肠癌、黑色素瘤、胰腺癌及腱鞘巨细胞瘤。局部晚期或转移性的<span style="color: black;">病人</span>，若标准治疗失败、<span style="color: black;">没</span>标准治疗<span style="color: black;">方法</span>或<span style="color: black;">没</span>法接受标准<span style="color: black;">方法</span>治疗，<span style="color: black;">能够</span><span style="color: black;">思虑</span>参加本项临床<span style="color: black;">实验</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">病人</span>福利！快参加“方舟援助计划”</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">“方舟援助计划”“由<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网联合<span style="color: black;">没</span>癌家园、权威基因检测<span style="color: black;">公司</span>、国际药厂、知名肿瘤中心发起的针对癌症基因突变肿瘤<span style="color: black;">病人</span>的活动。本计划旨在降低肿瘤<span style="color: black;">病人</span>基因检测<span style="color: black;">花费</span>，为<span style="color: black;">病人</span><span style="color: black;">供给</span>上市新药和未上市新药免费治疗的机会，多达上百种。参加“方舟援助计划”！为肿瘤<span style="color: black;">病人</span><span style="color: black;">连续</span><span style="color: black;">供给</span>抗癌<span style="color: black;">药品</span>带来的<span style="color: black;">存活</span><span style="color: black;">期盼</span>！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">想参加的病友<span style="color: black;">能够</span>将基因检测报告，诊断报告电子版或拍照发送至doctor.huang@globecancer.com,邮件中留下联系方式，医学部收到报告分析完毕后一个工作日内<span style="color: black;">tel</span>联系或直接致电<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部<span style="color: black;">评定</span>。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">非小细胞肺癌</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1JMT-101</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">EGFR20ins<span style="color: black;">插进</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率100%，我国自主<span style="color: black;">开发</span>广谱新药重磅登场！临床招募进行中</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">JMT101为人源化抗EGFR单克隆抗体，<span style="color: black;">拥有</span>自主知识产权，该<span style="color: black;">制品</span>相较于国内外已上市同类<span style="color: black;">制品</span>西妥昔单抗、帕尼单抗等<span style="color: black;">拥有</span>亲和力更高、免疫原性低、药效更优的特点。该<span style="color: black;">制品</span>已于2016年5月<span style="color: black;">得到</span>CFDA临床批件，现已进入I期临床<span style="color: black;">科研</span>，拟用于治疗非小细胞肺癌，结直肠癌等实体瘤。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2CT-707</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">ALK</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">有效率83.3%！创新型二代ALK<span style="color: black;">控制</span>剂CT-707临床招募中！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CT-707<span style="color: black;">是由于</span>我国首药控股自主<span style="color: black;">开发</span>、<span style="color: black;">拥有</span>完全知识产权的1类创新药，是全新结构的二代ALK<span style="color: black;">控制</span>剂。CT-707的<span style="color: black;">目的</span>人群是ALK阳性的非小细胞肺癌<span style="color: black;">病人</span>（包括初治的和克唑替尼耐药/不耐受的病人）。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3TQ-B3101</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">ROS1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">客观缓解率高达86%！新一代ROS1新药TPX-0005临床招募中</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">TQ-B3101胶囊是正大天晴自主研制的针对ROS1靶点的小分子靶向<span style="color: black;">控制</span>剂，在Ⅰ期<span style="color: black;">实验</span>中展现出了卓越的疗效。在<span style="color: black;">颁布</span>于2020 ASCO年会上的数据中，在接受350 mg bid治疗的8例<span style="color: black;">病人</span>中，整体缓解率达到了87.5%；<span style="color: black;">另外</span>，TQ-B3101<span style="color: black;">一样</span><span style="color: black;">拥有</span><span style="color: black;">经过</span>血脑屏障的能力，在基线有脑转移的8例<span style="color: black;">病人</span>中，整体缓解率达到了62.5%。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">4TPX-0005</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">ROS1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">客观缓解率高达86%！新一代广谱药TPX-0005或将<span style="color: black;">作为</span>下一个抗癌“传奇”</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Repotrectinib(瑞波替尼，代号TPX-0005)是美国TP Therapeutics<span style="color: black;">机构</span><span style="color: black;">开发</span>的第二代ALK/ROS1/TRK<span style="color: black;">控制</span>剂，<span style="color: black;">亦</span>是新一代的广谱抗癌药，临床证实其效力比克唑替尼高90倍。并且能够克服多种对其它TKI产生抗性的基因突变，杀死携带ROS1或NTRK基因融合的多种肿瘤细胞，因而有<span style="color: black;">潜能</span>治疗ROS1阳性的非小细胞肺癌，<span style="color: black;">拥有</span>惊人的入脑效果。除此之外，它还对ROS1、NTRK和ALK阳性的实体瘤<span style="color: black;">表示</span>出强大的抗癌活性。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">5伯瑞替尼</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">MET</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率94.4%！肺癌新药伯瑞替尼临床<span style="color: black;">实验</span>招募进行中</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">伯瑞替尼（PLB-1001，CBT-101）是一种有效的高<span style="color: black;">选取</span>性c-MET<span style="color: black;">控制</span>剂，在体外和<span style="color: black;">身体</span>NSCLC模型中均<span style="color: black;">表示</span>出优异的活性。I期临床<span style="color: black;">实验</span>结果<span style="color: black;">表示</span>：客观缓解率（ORR）为30.6%(11/36) ，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率（DCR）高达94.4% (34/36)。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">6谷美替尼</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">MET</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">非小细胞肺癌c-MET<span style="color: black;">控制</span>剂双星已出世，下一个“明星”是谁？</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">谷美替尼（SCC244）为结构全新、<span style="color: black;">持有</span>自主知识产权的新型c-MET<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>。<span style="color: black;">身体</span>外药效学、<span style="color: black;">功效</span>机制、<span style="color: black;">药品</span>代谢动力学以安全性<span style="color: black;">评估</span>等临床前<span style="color: black;">科研</span>证实，谷美替尼<span style="color: black;">拥有</span>安全、有效、质量可控等特点。<span style="color: black;">日前</span>谷美替尼已顺利<span style="color: black;">获准</span>进入临床Ⅰ期，治疗存在MET突变的晚期非小细胞肺癌患者的多中心临床<span style="color: black;">实验</span>正在<span style="color: black;">全世界</span>范围内开展。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">7HA121-28</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">RET</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">HA121-28 片在晚期实体瘤<span style="color: black;">病人</span>中的最大耐受剂量探索及单、多次给药药代动力学<span style="color: black;">科研</span> I 期临床<span style="color: black;">实验</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">HA121-28为一款口<span style="color: black;">吃下</span>药的多靶点<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>，<span style="color: black;">针对</span>EGFR、RET等靶点均有<span style="color: black;">控制</span>效果，<span style="color: black;">同期</span>具备抗血管生成和抗肿瘤的效果，<span style="color: black;">针对</span>肿瘤细胞和组织的杀伤能力更强，并具备广谱抗癌的<span style="color: black;">潜能</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">8马来酸苏特替尼胶囊</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">EGFR</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">马来酸苏特替尼胶囊治疗局部晚期或转移性非小细胞肺癌（仅限非耐药性罕见EGFR突变，L861Q、G719X和/或S768I）探索性临床<span style="color: black;">科研</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">苏特替尼是一种针对罕见EGFR基因突变的国产靶向药，是阿法替尼的同类药。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">9AMG510</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">KRAS</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">最终</span>来了！首个挑战KRAS的癌症克星-AMG510即将在中国开展临床<span style="color: black;">实验</span>！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">AMG510<span style="color: black;">便是</span>专门针对KRAS G12c突变亚型的。最初是在2013年被<span style="color: black;">开发</span>，是首个进入临床<span style="color: black;">实验</span>的KRAS<span style="color: black;">控制</span>剂。AMG 510<span style="color: black;">拥有</span>很高的<span style="color: black;">选取</span>性，仅与6,000多种蛋白质中的KRAS G12C结合，并且迄今为止在临床<span style="color: black;">科研</span>中<span style="color: black;">无</span><span style="color: black;">发掘</span>剂量限制性毒性。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">小细胞肺癌</p>
</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1盐酸米托蒽醌脂质体</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">/（化疗药）</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">全新化疗<span style="color: black;">方法</span>挑起小细胞肺癌治疗大旗！比多柔比星更安全的<span style="color: black;">药品</span>震撼登场！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">盐酸米托蒽醌脂质体为化疗<span style="color: black;">药品</span>，与多柔比星（阿霉素）同属于蒽环类<span style="color: black;">药品</span>，这一类<span style="color: black;">药品</span>的特点在于，它们能治疗的癌种比其他任何类型的化疗<span style="color: black;">药品</span>都要丰富，<span style="color: black;">同期</span>疗效较好，是<span style="color: black;">日前</span>最有效的化疗<span style="color: black;">方法</span>之一。适用蒽环类<span style="color: black;">药品</span>的癌种<span style="color: black;">包含</span>白血病、淋巴瘤、乳腺癌、子宫癌、卵巢癌和肺癌等。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">临床<span style="color: black;">科研</span><span style="color: black;">表示</span>，与多柔比星相比，米托蒽醌的心脏毒性较小，安全性更好。其抗肿瘤活性与多柔比星相当或略高，<span style="color: black;">同期</span><span style="color: black;">显著</span>高于环磷酰胺、氟尿嘧啶、甲氨喋呤、长春新碱和阿糖胞苷，且抗瘤谱广，可用于多个癌种的治疗。米托蒽醌与<span style="color: black;">非常多</span>常用抗肿瘤药有协同<span style="color: black;">功效</span>，与多柔比星<span style="color: black;">仅有</span>部分交叉耐药性。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2替雷丽珠单抗（BGB-A317）</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PD-1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">铂类<span style="color: black;">药品</span>+依托泊苷联合或不联合替雷利珠单抗（BGB-A317）用于未经治疗的广泛期小细胞肺癌<span style="color: black;">病人</span>的III期、随机、双盲、安慰剂对照<span style="color: black;">科研</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">替雷丽珠单抗（BGB-A317）为人源PD-1单抗，属于免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>，可与细胞表面的PD-1受体结合。BGB-A317对PD-1有很高的亲和性和特异性。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">胃癌</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1金妥昔单抗</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">VEGFR2/KDR</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">打破“<span style="color: black;">没</span>药可用”的局面！“国产版”胃癌“神药”雷莫芦单抗来了！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">金妥昔单抗是一款雷莫芦单抗的“Me Too”<span style="color: black;">药品</span>，<span style="color: black;">功效</span>机理<span style="color: black;">类似</span>，疗效<span style="color: black;">亦</span><span style="color: black;">类似</span>，同属于抗血管生成类<span style="color: black;">药品</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2Zolbetuximab（IMAB362）</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Claudin 18.2</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">胃癌靶点新秀、超50%<span style="color: black;">病人</span>的<span style="color: black;">期盼</span>之星！Claudin 18.2新药填补治疗空白！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Zolbetuximab针对<span style="color: black;">近期</span>大热的Claudin 18.2靶点，曾在2016年ASCO大会上公开了令人瞩目的优秀疗效数据，治疗局部晚期或转移性胃癌<span style="color: black;">病人</span>，将<span style="color: black;">病人</span>的<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期和总<span style="color: black;">存活</span>期延长了近一半。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3CAR-T</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Claudin 18.2</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">胃癌靶点新秀、超50%<span style="color: black;">病人</span>的<span style="color: black;">期盼</span>之星！Claudin 18.2新药填补治疗空白！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CAR-T细胞治疗属于免疫治疗的范畴，<span style="color: black;">日前</span>为止，<span style="color: black;">已然</span>在<span style="color: black;">包含</span>白血病和淋巴瘤等的治疗中展现出了卓越的疗效，并有多款疗法上市。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Claudin 18.2是胃癌的新兴靶点，其在所有胃癌中的检出率接近60%。CAR-T细胞疗法与Claudin 18.2靶点相结合，<span style="color: black;">能够</span>最大限度地覆盖到各类经标准治疗失败或耐药的<span style="color: black;">病人</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">4CS1001</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PD-L1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">一项比较CS1001联合奥沙利铂和卡培他滨(XELOX)化疗<span style="color: black;">方法</span>与安慰剂联合XELOX化疗<span style="color: black;">方法</span>在不可手术切除的局部晚期或转移性胃腺癌（GC）或胃食管结合部（GEJ）腺癌受试者中的疗效与安全性的多中心、双盲、随机化、III期<span style="color: black;">科研</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">科研</span><span style="color: black;">药品</span>“CS1001” <span style="color: black;">是由于</span>基石药业（苏州）有限<span style="color: black;">机构</span><span style="color: black;">开发</span>的重组抗程序性细胞死亡因子配体1（PD-L1）全人源化单克隆抗体。它可特异性结合PD-L1，阻断其与程序性细胞死亡因子-1（PD-1）的结合，从而恢复人<span style="color: black;">身体</span>T细胞杀伤肿瘤细胞的能力。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">肝癌</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1CAR-GPC3 T</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">GPC3</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">靶向GPC3 CAR-T细胞治疗肝细胞癌的<span style="color: black;">全世界</span>首个临床<span style="color: black;">实验</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">GPC3是一种细胞膜表面的硫酸乙酰肝素(HS)糖蛋白，是肝癌特异性<span style="color: black;">关联</span>抗原。GPC3的表达特点是在肝癌组织中过表达，而在正常肝组织不表达或低表达，基于GPC3特有的结构和功能特点,将其<span style="color: black;">做为</span>肝癌的治疗靶点，有可能<span style="color: black;">作为</span>治疗肝癌的有力武器。<span style="color: black;">科研</span>者在<span style="color: black;">全世界</span>率先开展了以GPC3为靶点的CAR-GPC3 T细胞治疗HCC的两项前瞻性Ⅰ期<span style="color: black;">科研</span>,为GPC3阳性HCC的治疗探索新的途径。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2特瑞普利单抗</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PD-1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">特瑞普利单抗 (JS001)联合贝伐珠单抗一线治疗晚期肝细胞癌 （HCC）的安全性和有效性的单臂、开放、多中心的 II 期临床<span style="color: black;">科研</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">特瑞普利单抗注射液）<span style="color: black;">做为</span>我国<span style="color: black;">准许</span>上市的首个国产以PD-1为靶点的单抗<span style="color: black;">药品</span>，<span style="color: black;">迄今</span>已在中、美等多国开展了覆盖14个瘤种的30多项临床<span style="color: black;">科研</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3信迪利单抗</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PD-1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">IBI310联合信迪利单抗治疗晚期肝细胞癌受试者的有效性和安全性的开放、单臂、Ib期<span style="color: black;">科研</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">重组全人源抗细胞毒T淋巴细胞<span style="color: black;">关联</span>抗原4（CTLA-4）单克隆抗体注射液（<span style="color: black;">开发</span>代号：IBI310）是信达生物制药（苏州）有限<span style="color: black;">机构</span>自主<span style="color: black;">开发</span>的一种全人源单克隆抗体。IBI310能特异性结合CTLA-4，从而阻断CTLA-4介导的T细胞<span style="color: black;">控制</span>，促进T细胞的激活和增殖，<span style="color: black;">加强</span>肿瘤免疫反应，达到抗肿瘤的效果。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">信迪利单抗为重组全人源IgG4型抗PD-1单克隆抗体注射液（<span style="color: black;">开发</span>代号：IBI308），是信达生物制药（苏州）有限<span style="color: black;">机构</span>自主<span style="color: black;">开发</span>的一种全人源单克隆抗体。2018年12月24日信迪利单抗正式在中国内地上市,适应症为经典霍奇金淋巴瘤。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">肝内胆管癌</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1ICP-192</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">FGFR</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">5年<span style="color: black;">存活</span>率不足5%，胆管癌的治疗困境该<span style="color: black;">怎样</span>打破？多款靶向<span style="color: black;">药品</span>重磅来袭！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">ICP-192为我国药企自主<span style="color: black;">开发</span>的第二代泛FGFR<span style="color: black;">控制</span>剂，对FGFR家族四个激酶均有很强的<span style="color: black;">控制</span>效果。FGFR全<span style="color: black;">叫作</span>成纤维细胞生长因子受体，是一类原癌基因，其突变可能<span style="color: black;">引起</span>的癌种<span style="color: black;">包含</span>肝内胆管癌和膀胱癌等。多种FGFR<span style="color: black;">控制</span>剂的临床<span style="color: black;">实验</span>数据<span style="color: black;">显示</span>，<span style="color: black;">非常多</span>FGFR变异类型的<span style="color: black;">病人</span>均可在FGFR<span style="color: black;">控制</span>剂治疗中获益。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">ICP-192为二代泛FGFR<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>，<span style="color: black;">拥有</span>特异性更强、药效更持久、对耐药突变仍然有效且有效性及安全性更高的特点，临床前<span style="color: black;">科研</span><span style="color: black;">已然</span>展现出了出色的<span style="color: black;">潜能</span>。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">乳腺癌</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1安瑞泽</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">HER2</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">安瑞泽（HS022）是一款赫赛汀（曲妥珠单抗）的国产仿制药，由浙江海正药业<span style="color: black;">开发</span>，<span style="color: black;">一样</span>针对HER-2靶点。<span style="color: black;">长时间</span><span style="color: black;">败兴</span>，曲妥珠单抗都是治疗乳腺癌最<span style="color: black;">要紧</span>的靶向<span style="color: black;">药品</span>，<span style="color: black;">做为</span>一款标准治疗<span style="color: black;">方法</span>，大大改善了乳腺癌<span style="color: black;">病人</span>的<span style="color: black;">存活</span><span style="color: black;">状况</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2普维替尼</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">FGFR</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">普维替尼是一款由我国自主<span style="color: black;">开发</span>的1.1类新药，属于一种小分子<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>，<span style="color: black;">针对</span>HER2靶点有较好的<span style="color: black;">控制</span>力，其治疗效果与曲妥珠单抗<span style="color: black;">类似</span>，<span style="color: black;">同期</span><span style="color: black;">拥有</span>治疗多种实体瘤的<span style="color: black;">潜能</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3阿特珠单抗</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PD-L1</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">三阴性乳腺癌的“救星”！靶向治疗困难？免疫疗法力挽狂澜！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">阿特珠单抗是首款<span style="color: black;">获准</span>用于治疗三阴性乳腺癌的免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>，适应症为与白蛋白结合性紫杉醇联合治疗不可手术切除的局部晚期或转移性三阴性乳腺癌<span style="color: black;">病人</span>，<span style="color: black;">病人</span>PD-L1表达水平≥1%。<span style="color: black;">这里</span>前<span style="color: black;">颁布</span>的数据中，接受阿特珠单抗+紫杉醇治疗的<span style="color: black;">病人</span>中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期为7.4个月，客观缓解率53%；而接受安慰剂+紫杉醇治疗的<span style="color: black;">病人</span>中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期为4.8个月，客观缓解率为33%</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">结直肠癌</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1JMT-101</p><span style="color: black;">功效</span>靶点
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">EGFR20ins<span style="color: black;">插进</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率100%，我国自主<span style="color: black;">开发</span>广谱新药重磅登场！临床招募进行中</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">JMT101为人源化抗EGFR单克隆抗体，<span style="color: black;">拥有</span>自主知识产权，该<span style="color: black;">制品</span>相较于国内外已上市同类<span style="color: black;">制品</span>西妥昔单抗、帕尼单抗等<span style="color: black;">拥有</span>亲和力更高、免疫原性低、药效更优的特点。该<span style="color: black;">制品</span>已于2016年5月<span style="color: black;">得到</span>CFDA临床批件，现已进入I期临床<span style="color: black;">科研</span>，拟用于治疗非小细胞肺癌，结直肠癌等实体瘤。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">恶性胸腹水，腹膜癌</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1SCB-313</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">/（化疗药）</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">痛！晚期恶性肿瘤<span style="color: black;">病人</span><span style="color: black;">出现</span>胸水、腹水该怎么办？</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">SCB-313是一款由我国三叶草生物制药自主<span style="color: black;">开发</span>的创新<span style="color: black;">药品</span>，为重组人肿瘤坏死因子<span style="color: black;">关联</span>凋亡诱导配体（TRAIL）-三聚体融合蛋白，<span style="color: black;">重点</span>用于治疗三项适应症（腹膜癌、恶性胸水、恶性腹水）的<span style="color: black;">病人</span>，<span style="color: black;">日前</span>有5项临床<span style="color: black;">实验</span>分别在中国和澳大利亚进行招募。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">胶质瘤</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1RX-108</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">PI3K突变的实体瘤、STK11</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">全新的抗癌靶标！关闭增殖、<span style="color: black;">起步</span>凋亡与自噬，让癌细胞“自取灭亡”！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">RX108是润新生物自主<span style="color: black;">开发</span>的全新小分子Na+/K+-ATP酶<span style="color: black;">控制</span>剂。Na+/K+-ATP酶是强心苷类<span style="color: black;">药品</span>的<span style="color: black;">重点</span><span style="color: black;">功效</span>靶点，新的<span style="color: black;">科研</span><span style="color: black;">显示</span>它与肿瘤细胞的<span style="color: black;">出现</span>、发展、迁移及分化<span style="color: black;">关联</span>，<span style="color: black;">控制</span>Na+/K+-ATP酶可<span style="color: black;">经过</span>多种途径发挥抗肿瘤<span style="color: black;">功效</span>，为研制新型抗肿瘤<span style="color: black;">药品</span>开辟了一个新的途径。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">膀胱癌</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1ICP-192</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">功效</span>靶点</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">FGFR</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">招募信息</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">膀胱癌<span style="color: black;">病人</span>长生<span style="color: black;">期盼</span>！中国自主<span style="color: black;">开发</span>新药ICP-192重磅登场！</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">举荐</span>指数</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">★★★★★</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">ICP-192为我国药企自主<span style="color: black;">开发</span>的第二代泛FGFR<span style="color: black;">控制</span>剂，对FGFR家族四个激酶均有很强的<span style="color: black;">控制</span>效果。FGFR全<span style="color: black;">叫作</span>成纤维细胞生长因子受体，是一类原癌基因，其突变可能<span style="color: black;">引起</span>的癌种<span style="color: black;">包含</span>肝内胆管癌和膀胱癌等。多种FGFR<span style="color: black;">控制</span>剂的临床<span style="color: black;">实验</span>数据<span style="color: black;">显示</span>，<span style="color: black;">非常多</span>FGFR变异类型的<span style="color: black;">病人</span>均可在FGFR<span style="color: black;">控制</span>剂治疗中获益。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">ICP-192为二代泛FGFR<span style="color: black;">控制</span>剂<span style="color: black;">药品</span>，<span style="color: black;">拥有</span>特异性更强、药效更持久、对耐药突变仍然有效且有效性及安全性更高的特点，临床前<span style="color: black;">科研</span><span style="color: black;">已然</span>展现出了出色的<span style="color: black;">潜能</span>。</p>
请问、你好、求解、谁知道等。 期待与你深入交流，共探知识的无穷魅力。 i免费外链发布平台 http://www.fok120.com/
页:
[1]